Novo Nordisk Q2 EPS $1.26 Misses $1.28 Estimate, Sales $7.94B Miss $7.97B Estimate
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk (NYSE:NVO) reported Q2 earnings of $1.26 per share, missing the analyst consensus estimate of $1.28 by 1.56%. The company also reported quarterly sales of $7.94 billion, missing the analyst consensus estimate of $7.97 billion by 0.39%. Despite the misses, both earnings and sales show significant increases compared to the same period last year.
August 10, 2023 | 7:29 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk's Q2 earnings and sales missed analyst estimates, which could negatively impact the stock in the short term. However, the YoY growth in both earnings and sales might mitigate this impact.
Novo Nordisk's Q2 earnings and sales missed analyst estimates, which could lead to a negative sentiment among investors and a potential drop in the stock price. However, the significant YoY growth in both earnings and sales might be seen as a positive sign of the company's performance, potentially mitigating the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100